The Journal of Clinical Investigation created a video illustrating that local delivery of the complement C3 inhibitor AMY-101 in patients with gingivitis was safe, well tolerated, and led to significant and sustained reduction of clinical indices of gingival inflammation.
Original article: Hasturk H, Hajishengallis G, Lambris JD, Mastellos DC, Yancopoulou D. (2021). Phase 2a clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation. J Clin Invest. 131: e152973.